Tian Li-Jun, Liu Hong-Zhi, Zhang Qiang, Geng Dian-Zhong, Huo Yu-Qing, Xu Shou-Jian, Hao Yan-Zhang
Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China.
Department of Orthopedics, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China.
Cancer Manag Res. 2021 Jul 8;13:5457-5466. doi: 10.2147/CMAR.S294313. eCollection 2021.
To evaluate the efficacy and safety of combined-modality therapy for elderly patients with locally advanced non-small-cell lung cancer (NSCLC) invading the chest wall.
We retrospectively enrolled 21 elderly patients (aged ≥60 years) with locally advanced NSCLC invading the chest wall. For external beam radiotherapy (EBRT) of the primary tumor, 40Gy was applied and supplemented with iodine-125 seed implantation while 60Gy was applied to the lymph nodes of the mediastinum. Follow-up was conducted every 3 months postoperatively. The related analytic parameters were change in tumor size, the objective response rate (ORR), the disease control rate (DCR), the degree of pain relief, the improvement of physical status, and toxicity.
The combined-modality therapy significantly inhibited local growth of the tumor (from 7.84±1.20 to 4.69±1.90 cm) ( <0.0001), with 71.4% ORR and 90.5% DCR at 1 year. The cancer-related pain was significantly relieved ( <0.05) and physical status was significantly improved ( <0.05). No procedure-associated death or grade > 2 irradiation-related adverse effects were reported in this study.
The combined-modality therapy of EBRT with 40Gy and permanent iodine-125 seed implantation is an efficacious and safe treatment option for elderly patients with locally advanced NSCLC invading the chest wall.
评估综合治疗对侵犯胸壁的老年局部晚期非小细胞肺癌(NSCLC)患者的疗效和安全性。
我们回顾性纳入了21例侵犯胸壁的老年局部晚期NSCLC患者(年龄≥60岁)。对于原发肿瘤的外照射放疗(EBRT),给予40Gy并辅以碘-125粒子植入,而纵隔淋巴结给予60Gy。术后每3个月进行一次随访。相关分析参数包括肿瘤大小变化、客观缓解率(ORR)、疾病控制率(DCR)、疼痛缓解程度、身体状况改善情况及毒性。
综合治疗显著抑制了肿瘤的局部生长(从7.84±1.20 cm缩小至4.69±1.90 cm)(P<0.0001),1年时ORR为71.4%,DCR为90.5%。癌症相关疼痛明显缓解(P<0.05),身体状况显著改善(P<0.05)。本研究未报告与手术相关的死亡或3级以上的放疗相关不良反应。
40Gy的EBRT与永久性碘-125粒子植入的综合治疗是侵犯胸壁的老年局部晚期NSCLC患者的一种有效且安全的治疗选择。